|

Lupus Clinical Trials in Fort Worth, TX

26 recruiting studies within 50 miles

Phase
Trial Phase Dist.
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusPhase 32 mi
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)Phase 42 mi
Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy TrialPhase 42 mi
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPhase 12 mi
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus ErythematosusPhase 213 mi
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)Phase 213 mi
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusPhase 2/313 mi
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus ErythematosusPhase 313 mi
A Study of Obexelimab in Patients With Systemic Lupus ErythematosusPhase 217 mi
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE ParticipantsPhase 1/223 mi
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus NephritisPhase 431 mi
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD ParticipantsPhase 131 mi
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)Phase 1/231 mi
Cutaneous Lupus Registry—31 mi
Lupus Landmark Study: A Prospective Registry and Biorepository—31 mi
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)Phase 131 mi
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- VPhase 231 mi
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)Phase 231 mi
Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus—31 mi
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)Phase 135 mi
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).Phase 335 mi
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus ErythematosusPhase 341 mi
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus ErythematosusPhase 141 mi
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE ParticipantsPhase 145 mi
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseasePhase 345 mi
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)Phase 145 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.